A Phase I/II Study of 2'-Deoxy-3'-Thiacytidine (Lamivudine) in Patients with Advanced Human Immunodeficiency Virus Infection

Autor: Catherine A. Vicary, Steven N. Warthan, James M. Pluda, John Ruedy, Timothy P. Cooley, Nancy E. Reinhalter, Julio S. G. Montaner, Robert Yarchoan, Mark A. Wainberg, Joseph B. Quinn, Laura E. Shay, Hilary M. Hirst, Marc Rubin, Geoffrey J. Yuen

Publikováno v: Journal of Infectious Diseases. 171:1438-1447

In a phase I/II trial assessing the toxicity, pharmacokinetics, and activity of the (-)enantiomer of 2'-deoxy-3'-thiacytidine (3TC, lamivudine), 97 patients with AIDS or advanced human immunodeficiency virus (HIV) disease were administered 3TC at 0.5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7db46ba8ad260e85d3e389f2061c9dcd
https://doi.org/10.1093/infdis/171.6.1438

Efficacy and safety of the neuraminidase inhibitor Zanamivir in the treatment of influenzavirus infections

Autor: Albert D. M. E. Osterhaus, Oliver N. Keene, Frederick G. Hayden, Arthur M. Bohnen, Hilary M. Hirst, D. M. Fleming, Kevin Wightman, Karl G. Nicholson, John J. Treanor, Fred Y. Aoki

Publikováno v: New England Journal of Medicine, 874-881. Massachussetts Medical Society
ISSUE=337;STARTPAGE=874;ENDPAGE=881;ISSN=0028-4793;TITLE=New England Journal of Medicine

Background: The sialic acid analogue zanamivir (GG167) is a selective inhibitor of influenza A and B virus neuraminidases. These viral enzymes are essential for the release of virus from infected cells, and they may also reduce the inactivation of vi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a4f9096afeb49b60954aaf03ea24a15
https://pure.eur.nl/en/publications/4d63d816-c0a1-4a26-95d3-dd785bb1f263